TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma

被引：0
|
作者：
Reiter, Florian P. [1 ]
Geier, Andreas [1 ]
机构：
[1] Univ Hosp Wurzburg, Dept Med 2, Div Hepatol, D-97080 Wurzburg, Germany
来源：
LANCET | 2025年 / 405卷 / 10474期
关键词：
LOCOREGIONAL THERAPIES; END-POINTS; SURVIVAL;
D O I：
10.1016/S0140-6736(24)02680-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：174 / 176
页数：3
相关论文
共 50 条
  • [1] Predictive Biomarkers of Immune Checkpoint Inhibitor-Based Mono- and Combination Therapies for Hepatocellular Carcinoma
    Jeng, Long-Bin
    Wang, John
    Teng, Chiao-Fang
    JOURNAL OF CANCER, 2024, 15 (02): : 484 - 493
  • [2] Letter to the editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma
    Jin, Zhi-Cheng
    Chen, Jian-Jian
    Luo, Biao
    Zhang, Wei-Hua
    Teng, Gao-Jun
    HEPATOLOGY, 2023, 77 (01) : E5 - E6
  • [3] FIRST-LINE IMMUNE CHECKPOINT INHIBITOR-BASED SEQUENTIAL THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: A RATIONALE FOR FUTURE TRIALS
    Cabibbo, G.
    Celsa, C.
    Battaglia, S.
    Enea, M. .
    Rizzo, G. E. M.
    Busacca, A.
    Petta, S.
    Calvaruso, V.
    Di Marco, V.
    Craxi, A.
    Camma, C.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S107 - S107
  • [4] First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials
    Cabibbo, Giuseppe
    Reig, Maria
    Celsa, Ciro
    Torres, Ferran
    Battaglia, Salvatore
    Enea, Marco
    Rizzo, Giacomo Emanuele Maria
    Petta, Salvatore
    Calvaruso, Vincenza
    Di Marco, Vito
    Craxi, Antonio
    Singal, Amit G.
    Bruix, Jordi
    Camma, Calogero
    LIVER CANCER, 2021, : 75 - 84
  • [5] Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
    Michielin, Olivier
    Lalani, Aly-Khan
    Robert, Caroline
    Sharma, Padmanee
    Peters, Solange
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [6] Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study
    Daniel Roessler
    Osman Öcal
    Alexander B. Philipp
    Daniel Markwardt
    Stefan Munker
    Julia Mayerle
    Leonie S. Jochheim
    Katharina Hammer
    Christian M. Lange
    Andreas Geier
    Max Seidensticker
    Florian P. Reiter
    Enrico N. De Toni
    Najib Ben Khaled
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 3065 - 3073
  • [7] Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study
    Roessler, Daniel
    Oecal, Osman
    Philipp, Alexander B.
    Markwardt, Daniel
    Munker, Stefan
    Mayerle, Julia
    Jochheim, Leonie S.
    Hammer, Katharina
    Lange, Christian M.
    Geier, Andreas
    Seidensticker, Max
    Reiter, Florian P.
    De Toni, Enrico N.
    Ben Khaled, Najib
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3065 - 3073
  • [8] Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma
    Kim, Ha Il
    Lim, Jihye
    Shim, Ju Hyun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 2069 - 2077
  • [9] Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma
    Ha Il Kim
    Jihye Lim
    Ju Hyun Shim
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2069 - 2077
  • [10] VIRAL ETIOLOGY DETERMINES OUTCOMES OF IMMUNE CHECKPOINT INHIBITOR-BASED COMBINATION THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Wu, Chi-Jung
    Lee, Pei-Chang
    Hung, Ya-Wen
    Lee, Chieh-Ju
    Chi, Chen-Ta
    Lee, I-Cheng
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    HEPATOLOGY, 2022, 76 : S1376 - S1376
12345